Fragment-based lead discovery: Practical aspects of NMR/SPR-based fragment screening
- At: 2009 FIP Congress in Istanbul (Turkey)
- Type: Presentation
- By: MIURA, Takaaki (Chugai Pharmaceutical Co., Ltd., Kamakura, kanagawa, Japan)
Fragment-based lead discovery (FBLD) has recently emerged as an alternative drug discovery approach to traditional high throughput screening, and has been rapidly integrated into discovery programs in many pharmaceutical companies. In FBLD, weak but specifically binding small "fragments" with MW of ca. 250, are first identified by screening of a.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.